Development of a sensitive RT-PCR method for amplifying and sequencing near full-length HCV genotype 1 RNA from patient samples

Virology Journal

Volumn 10, Issue , 2013, Pages

  Zhang, Eileen Z ^a   Bartels, Doug J ^a   Frantz, J Dan ^a   Seepersaud, Sheila ^a   Lippke, Judith A ^a   Shames, Benjamin ^a   Zhou, Yi ^a   Lin, Chao ^a   Kwong, Ann ^a   Kieffer, Tara L ^a  

^a VERTEX PHARMACEUTICALS   (United States)

Author keywords

Direct Acting Antiviral Agents (DAA); Genotype; Hepatitis C Virus (HCV); Lower Limit of Detection (LLOD); NS (Non structural); NS3 4A; NS4B; NS5A; NS5B; Quasispecies; Resistance; Reverse Transcription Polymerase Chain Reaction (RT PCR); Sequencing

Indexed keywords

COMPLEMENTARY DNA; VIRUS RNA;

ARTICLE; CONCENTRATION (PARAMETERS); DNA SYNTHESIS; GENE AMPLIFICATION; GENOTYPE; HEPATITIS C VIRUS; HUMAN; LIMIT OF DETECTION; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; VIRUS GENE;

ANTIVIRAL AGENTS; DRUG RESISTANCE, VIRAL; GENOME, VIRAL; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR BIOLOGY; MUTATION; PLASMA; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, VIRAL; SEQUENCE ANALYSIS, DNA; VIROLOGY;

HEPATITIS C VIRUS;

EID: 84873699985     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-10-53     Document Type: Article

References (29)

1. Hepatitis C virus infection: the new global epidemic. Butt AA, Expert Rev Anti Infect Ther 2005 3 241 249 10.1586/14787210.3.2.241 15918781 (Pubitemid 40598003)
2. The burden of hepatitis C in the United States. Kim WR, Hepatology 2002 36 30 S34 12407574
3. The global burden of hepatitis C. Lavanchy D, Liver Int 2009 29 Suppl 1 74 81 19207969
4. Telaprevir for previously untreated chronic hepatitis C virus infection. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, Muir AJ, Ferenci P, Flisiak R, George J, Rizzetto M, Shouval D, Sola R, Terg RA, Yoshida EM, Adda N, Bengtsson L, Sankoh AJ, Kieffer TL, George S, Kauffman RS, Zeuzem S, N Engl J Med 2011 364 2405 2416 10.1056/NEJMoa1012912 21696307
5. Telaprevir for retreatment of HCV infection. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, Mullhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M, N Engl J Med 2011 364 2417 2428 10.1056/NEJMoa1013086 21696308
6. Hepatitis C. Ray SC, Thomas DL, Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases Elsevier, Amsterdam, Mandell G, Bennett JE, Dolin R, 7 2009 2157 2187
7. Genetic diversity and evolution of hepatitis C virus-15 years on. Simmonds P, J Gen Virol 2004 85 3173 3188 10.1099/vir.0.80401-0 15483230 (Pubitemid 39445434)
8. Rapid decrease of wild-type hepatitis C virus on telaprevir treatment. Adiwijaya BS, Hare B, Caron PR, Randle JC, Neumann AU, Reesink HW, Zeuzem S, Herrmann E, Antivir Ther 2009 14 591 595 19578245
9. Sequence and phenotypic analysis for resistance monitoring in hepatitis C virus drug development: recommendations from the HCV DRAG. Kwong AD, Najera I, Bechtel J, Bowden S, Fitzgibbon J, Harrington P, Kempf D, Kieffer TL, Koletzki D, Kukolj G, Lim S, Pilot-Matias T, Lin K, Mani N, Mo H, O'Rear J, Otto M, Parkin N, Pawlotsky JM, Petropoulos C, Picchio G, Ralston R, Reeves JD, Schooley RT, Seiwert S, Standring D, Stuyver L, Sullivan J, Miller V, Gastroenterology 2011 140 755 760 10.1053/j.gastro.2011.01.029 21255574
10. Mixing and matching drugs: what makes sense? Welzel TM, Zeuzem S, Clin Liver Dis 2011 15 657 664 10.1016/j.cld.2011.05.012 21867943
11. Full-length complementary DNA of hepatitis C virus genome from an infectious blood sample. Aizaki H, Aoki Y, Harada T, Ishii K, Suzuki T, Nagamori S, Toda G, Matsuura Y, Miyamura T, Hepatology 1998 27 621 627 10.1002/hep.510270242 9462666 (Pubitemid 28081082)
12. Accurate representation of the hepatitis C virus quasispecies in 5.2-kilobase amplicons. Liu Z, Netski DM, Mao Q, Laeyendecker O, Ticehurst JR, Wang XH, Thomas DL, Ray SC, J Clin Microbiol 2004 42 4223 4229 10.1128/JCM.42.9.4223-4229.2004 15365015 (Pubitemid 39296148)
13. A refined long RT-PCR technique to amplify complete viral RNA genome sequences from clinical samples: application to a novel hepatitis C virus variant of genotype 6. Lu L, Nakano T, Smallwood GA, Heffron TG, Robertson BH, Hagedorn CH, J Virol Methods 2005 126 139 148 10.1016/j.jviromet.2005.01.031 15847930 (Pubitemid 40558754)
14. Long PCR and its application to hepatitis viruses: amplification of hepatitis A, hepatitis B, and hepatitis C virus genomes. Tellier R, Bukh J, Emerson SU, Miller RH, Purcell RH, J Clin Microbiol 1996 34 3085 3091 8940452 (Pubitemid 26389362)
15. Efficient amplification and cloning of near full-length hepatitis C virus genome from clinical samples. Fan X, Xu Y, Di Bisceglie AM, Biochem Biophys Res Comm 2006 346 1163 1172 10.1016/j.bbrc.2006.06.039 16793008 (Pubitemid 43946818)
16. Comparative analysis of nearly full-length hepatitis C virus quasispecies from patients experiencing viral breakthrough during antiviral therapy: clustered mutations in three functional genes, E2, NS2, and NS5a. Xu Z, Fan X, Xu Y, Di Bisceglie AM, J Virol 2008 82 9417 9424 10.1128/JVI.00896-08 18667493
17. Separation of near full-length hepatitis C virus quasispecies variants from a complex population. Zhou D, Fan X, Tan D, Xu Y, Tavis JE, Di Bisceglie AM, J Virol Methods 2007 141 220 224 10.1016/j.jviromet.2006.12.002 17208310 (Pubitemid 46466970)
18. INCIVEK™ US perscribing information Vertex Pharmaceuticals Incorporated, Cambridge, MA 2012
19. INCIVO® EU Summary of Product Characteristics Janssen Pharmaceuticals, Beerse, Belgium 2012
20. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. Hézode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S, N Engl J Med 2009 360 1839 1850 10.1056/NEJMoa0807650 19403903
21. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, McNair L, Alam J, Muir AJ, N Engl J Med 2009 360 1827 1838 Erratum: N Engl J Med. 2009, 361:1516 10.1056/NEJMoa0806104 19403902
22. Telaprevir for previously treated chronic HCV infection. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM, N Engl J Med 2010 362 1292 1303 Erratum: N Engl J Med. 2010, 362:1647. 10.1056/NEJMoa0908014 20375406
23. Response-guided telaprevir combination treatment for hepatitis C virus infection. Sherman KE, Flamm SL, Afdhal NH, Nelson DR, Sulkowski MS, Everson GT, Fried MW, Adler M, Reesink HW, Martin M, Sankoh AJ, Adda N, Kauffman RS, George S, Wright CI, Poordad F, N Engl J Med 2011 365 1014 1024 Erratum: N Engl J Med. 2011, 365:1551 10.1056/NEJMoa1014463 21916639
24. The Los Alamos HCV sequence database. Kuiken C, Yusim K, Boykin L, Richardson R, Bioinformatics 2005 21 3 379 384 10.1093/bioinformatics/bth485 15377502 (Pubitemid 40246609)
25. Betaine improves the PCR amplification of GC-rich DNA sequences. Henke W, Herdel K, Jung K, Schnorr D, Loening SA, Nucleic Acids Res 1997 25 3957 3958 10.1093/nar/25.19.3957 9380524 (Pubitemid 27420509)
26. Betaine can eliminate the base pair composition dependence of DNA melting. Rees WA, Yager TD, Korte J, von Hippel PH, Biochemistry 1993 32 137 144 10.1021/bi00052a019 8418834 (Pubitemid 23033330)
27. A Mathematical Theory of Communication. Shannon Claude E, Bell Syst Tech J 1948 27 3 379 423
28. Hepatitis C viral evolution in genotype 1 treatment-naive and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G, PLoS One 2012 7 34372 10.1371/journal.pone.0034372 22511937
29. Kwong AD, Frantz JD, Bartels DJ, Lin C, Shames B, Seepersaud S, Lippke JA, Kieffer TL, Zhou Y, Zhang EZ, Sullivan JC, inventors; Vertex Pharmaceuticals Incorporated, assignee, Methods for amplifying hepatitis C virus nucleic acids 2010 US patent WO/20120/090857 2010